FDA Office of Generic Drugs Question-Based Review Initiative: An Update

FDA Office of Generic Drugs Question-Based Review Initiative: An Update

May 29, 2009

News

Article

Pharmaceutical TechnologyPharmaceutical Technology-06-02-2009

Volume 33

Issue 6

The Question-Based Review (QbR) initiative of the Office of Generic Drugs has reached its second full year in 2009. Special from the Journal of Validation Technology.

This article was published in the Journal of Validation Technology, Spring 2009, Volume 15, Number 2. Authors Aloka Srinivasan and Robert Iser provide an update on the Question-Based Review Initiative by FDA's Office of Generic Drugs. Read about the initiative on gxpandjvt.com.

Articles in this issue

Quality in, Quality Out

Quarantine at a Glance

Drug Serialization and Supply-Chain Security

Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 2 of 2

Pharmacosomes: A Potential Alternative to Conventional Vesicular Systems

Package Design Boosts Patient Compliance

Truth and Transparency

Outsourcing Clinical Trial Materials

Penny-Wise, Pound-Foolish

Mapping Opportunities for Patent Positions

Beneath the Surface

Operator Error

Charting a Pathway to Follow-On Biologics

In the Spotlight June 2009

Report From: Ireland

Related Content

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

AstraZeneca and Alteogen Sign License Agreement for Developing Subcutaneous Formulations of Oncology Assets

Feliza Mirasol

March 25th 2025

Article

Under the agreement, AstraZeneca will use Alteogen’s proprietary hyaluronidase platform technology to develop and commercialize subcutaneous formulations of multiple oncology assets in its portfolio.

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024

Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.

Magnified View of Lipid Nanoparticles | Image Credit: ©Aniwat - stock.adobe.com

Organic Nanoparticle-Based Drug-Delivery Systems as Alternatives to Lipid Nanoparticles

Cynthia A. Challener

March 9th 2025

Article

Exosomes, polymeric nanoparticles, and DNA nanostructures offer many potential advantages.

Drug Solutions Podcast: The Biosimilars Landscape

Feliza Mirasol

January 31st 2024

Podcast

In this episode of the Drug Solutions Podcast, industry experts give an overview of the biosimilars market and discuss factors affecting not only their manufacture, but their upstake in the market as well.